Droxidopa Research Articles

Role of Droxidopa for Neurogenic Orthostatic Hypotension Still Unclear

Neurogenic orthostatic hypotension is a clinical syndrome characterized by a sustained drop in blood pressure upon becoming upright that leads to

Lundbeck Adds to Neurology Portfolio with Chelsea Therapeutics Acquisition

H. Lundbeck has agreed to buy Chelsea Therapeutics for US$530 M upfront in order to add the orphan drug Northera™ (droxidopa) to its US neurology portfolio. After previously being rejected by the US FDA, Northera was granted accelerated approval in February 2014 for the treatment of symptomatic neurogenic orthostatic hypotension. Chelsea shareholders will also receive contingent value rights that could pay up to US$1.50 per share dependent on sales levels of Northera in the period 2015-2017, bringing the potential total deal value to US$658 M.

Accelerated FDA Approval for Droxidopa to Treat Orthostatic Hypotension

The U.S. Food and Drug Administration recently granted approval for the use of droxidopa to treat neurogenic orthostatic hypotension (NOH). NOH, also

A novel electrochemical sensor based on ZnO nanoparticle and ionic liquid binder for square wave voltammetric determination of droxidopa in pharmaceutical and urine samples

Synthesis and application of ZnO nanoparticles (Zn/NPs) and 1-butyl-3-methylimidazolium hexafluoro phosphate as high sensitive sensors for voltammetric determination of droxidopa (DXP) using carbon paste electrode has been reported for the first time. The synthesized nanoparticles were characterized by different methods such as TEM, SEM and XRD. The electrochemical oxidation of DXP on the new ZnO/NPs ionic liquid carbon paste electrode (ZnO/NPs/IL/CPE) has been carefully studied. The experimental results suggested that the modified electrode promoted electron transfer reaction for the oxidation of DXP. Under the optimized conditions of pH 7.0, the plot of peak current vs. DXP concentration consisted of two linear segments with slopes of 0.4733 and 0.0177μAμmol−1L in the concentration ranges 0.4–5.0μmolL−1 and 5.0–310.0μmolL−1, respectively. The detection limit was 0.15μmolL−1. The proposed method was successfully applied for the determination of DXP in tablet, serum and urine samples.

Droxidopa fast tracked for NOH in the US.

Droxidopa fast tracked for NOH in the US.